REG - Genus - Ruthin Site Visit

GenusAnnouncement

03/11/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221103:nRSC1089Fa&default-theme=true

RNS Number : 1089F  Genus PLC  03 November 2022

   3 November 2022

Genus plc

 

Ruthin Site Visit

 

Genus plc (LSE: GNS), a leading global animal genetics company, is today
hosting a site visit for sell side analysts and institutional investors to its
production site in Ruthin, North Wales.  The visit will showcase Genus's
world class beef and dairy bulls, as well as its industry leading Intelligen
technology.

No new information regarding current trading will be disclosed during the site
visit.

Enquiries:

 Genus plc                                     Tel: 01256 345970

 Stephen Wilson, Chief Executive Officer

 Alison Henriksen, Chief Financial Officer

 Buchanan                                      Tel: 0207 466 5000

 Charles Ryland / Chris Lane / Verity Parker

 

About Genus

Genus advances animal breeding and genetic improvement by applying
biotechnology and sells added value products for livestock farming and food
producers. Its technology is applicable across livestock species and is
currently commercialised by Genus in the dairy, beef and pork food production
sectors.

Genus's worldwide sales are made in over 75 countries under the trademarks
'ABS' (dairy and beef cattle) and 'PIC' (pigs) and comprise semen, embryos and
breeding animals with superior genetics to those animals currently in farms.
Genus's customers' animals produce offspring with greater production
efficiency and quality, and our customers use them to supply the global dairy
and meat supply chains.

Genus's competitive edge comes from the ownership and control of proprietary
lines of breeding animals, the biotechnology used to improve them and its
global supply chain, technical service and sales and distribution network.

Headquartered in Basingstoke, United Kingdom, Genus companies operate in over
24 countries on six continents, with research laboratories located in Madison,
Wisconsin, USA.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKBBDNBDDADK